Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

• Bladder
• Breast
• Colon
• Gastrointestinal
• Hematology
• Hepatic
• Leukemia
• Lung
• Lymphoma
• Melanoma
• Myelomas
• Ovarian
• Pancreatic
• Prostate
• Renal
• Solid Tumors

 

Bladder

• A study of Enfortumab Vedotin for urothelial cancer

  A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
  

  ---

• IMMU-132 for Metastatic Urothelial Cancer

  A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)
  

  ---

Breast

• A Phase 3 study of LY3484356 vs Investigator’s choice of endocrine therapy in Breast Cancer

  A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator’s Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy
  

  ---

• A Phase IB/II study of durvalumab + datopotamab deruxtecan in Breast Cancer

  A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer
  

  ---

• Phase 3 study of Letrozole +/- SAR439859 in Breast Cancer

  A randomized, multicenter, double-blind phase 3 study of amcenestrant (SAR439859) plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease
  

  ---

• Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

  Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
  

  ---

• Phase 1a/1b Study of LY3484356 in Metastatic Breast Cancer Patient

  A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
  

  ---

• Phase I Study of D-0502 +/- Palbociclib in Her2 Negative Breast Cancer

  A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination with Palbociclib in Women With Advanced or Metastatic ER- Positive and HER2-Negative Breast Cancer
  

  ---

• Phase 2 of Tucatinib in Combination with Trastuzumab Deruxtecan

  A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer
  

  ---

• Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab

  Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
  

  ---

Colon

• A Phase 3 study of MRTX849 + Cetuximab vs. Chemotherapy in Colorectal Cancer

  A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
  

  ---

• Phase 3 Lenvatinib in combination with Pembrolizumab vs. SOC for colorectal cancer

  A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment
  

  ---

• Phase 3 Study of Olaparib in Metastatic Colorectal Cancer Patients

  A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab
  

  ---

• Phase 3 Trilaciclib/Placebo in Metastatic Colorectal Cancer

  A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
  

  ---

• Phase 3b for MSI-H or MMR Colorectal Cancer Patients

  A Phase 3b Randomized Clinical Trial of Nivolumab Alone, or in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
  

  ---

Gastrointestinal

• Phase 3 Study of INCMGA00012 in Anal Cancer

  A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy
  

  ---

• Phase 3 Study of Sintilimab in Esophageal Cancer

  A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
  

  ---

Hematology

• A Phase 2 study of Selinexor vs Physician’s choice in patients with Myelofibrosis

  A PHASE 2, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIANíS CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS
  

  ---

• Phase 3 Study of Navitoclax in Myelofibrosis

  A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis
  

  ---

• Phase 3 Study of Pacritinib in Severe Thrombocytopenia

  A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia
  

  ---

Hepatic

• Phase 2 Study of MK-1308A + Lenvatinib in First Line Hepatocellular Cancer

  A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (MK1308/MK3475) in Combination with Lenvatinib (E7080/MK7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
  

  ---

Leukemia

• A Phase 1b study of TG-1801 with or without Ublituximab in subjects with B-Cell Lymphoma or CLL

  A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia
  

  ---

• A Phase 3b Study of asciminib chronic myeloid leukemia

  An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation
  

  ---

• Phase 3 Study of LOXO-305 in CLL/SLL Patients

  A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  

  ---

• Phase 2 Study of Ublituximab in Combination with Umbralisib and Venetoclax for CLL patients

  Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia
  

  ---

• Phase III of Obinutuzumab and Venetoclax in Untreated CLL without 17p deletion or Tp53 mutation

  A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION
  

  ---

Lung

• A Phase 3 study of subcutaneous Pembrolizumab vs. Chemo in Lung Cancer

  A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer
  

  ---

• A Phase 3 study of Adjuvant Selpercatinib in lung cancer

  A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC
  

  ---

• A Phase III study of Osimertinib +/- Platinum and Pemextred Chemotherapy in Lung Cancer

  A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer
  

  ---

• Phase 2 Study of VS-6766 +/- Defactinib in Lung Cancer

  A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer
  

  ---

• Phase 3 Study of MRTX849 in Lung Cancer

  A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
  

  ---

• Phase 3 Study of Amivantamab and Lazertinib in Lung Cancer

  A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  

  ---

• Phase 3 Study of Amivantamab in Lung Cancer

  A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  

  ---

• Phase 2 Study of AB122 and AB154 in Front Line Non-Small Cell Lung Cancer Patients

  A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
  

  ---

• Phase 1/2 Study of NKTR-214 in Patients with Locally Advanced/Metastatic Solid Tumors

  
  

  ---

• Phase III Study of Atezolizumab in Combination with Cabozantinib for previously treated Lung Cancer

  A Phase III, Multicenter, Randomized, Open-Label, Controlled Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab given in combination with Cabozantinib versus Docetaxel Monotherapy in Patients with Metastatic Non Small Cell Lung Cancer Previously Treated With an Anti PD-L1/PD-1 Antibody And Platinum-Containing Chemotherapy
  

  ---

• Phase 2 Study of Telaglenastat in 1st line Metastatic KEAP/NRF-2 mutated Non-Small Cell Lung Cancer

  A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer
  

  ---

• Canakinumab for Adjuvant Non-Small Cell Lung Cancer

  A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer
  

  ---

Lymphoma

• Phase 3 study of tafasitamab plus lenalidomide with R-CHOP vs R-CHOP in DLBCL

  A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma
  

  ---

• A Phase 1b study of TG-1801 with or without Ublituximab in subjects with B-Cell Lymphoma or CLL

  A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination with Ublituximab in Subjects with B-Cell Lymphoma or Chronic Lymphocytic Leukemia
  

  ---

• Phase 3 Study of Acalabrutinib in Untreated Diffuse Large B-Cell Lymphoma

  A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
  

  ---

• Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

  Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
  

  ---

• Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

  A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above
  

  ---

Melanoma

• Phase 3 Study of Adjuvant Immunotherapy in Melanoma Patients

  A Phase 3, Randomized, Open-label Study of Adjuvant Immunotherapy with Bempegaldesleukin with Nivolumab Versus Nivolumab after Complete resection of Melanoma in Participants at High Risk for Recurrence
  

  ---

Myelomas

• Phase II Study for 1st or 2nd Relapse of Multiple Myeloma

  An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone
  

  ---

Ovarian

• Phase 2 Study ofVS-6766 +/- Defactinib in Ovarian Cancer

  A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer
  

  ---

Pancreatic

• Phase 2 Study of SBRT with GC4711 for Unresectable, Non-Metastatic Pancreatic Cancer

  A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
  

  ---

• Tumor Treating Fields with Gemzar/Nab-Paclitaxel for Pancreatic Cancer

  Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
  

  ---

Prostate

• A Phase 3 study Abiraterone + Capivasertib/Placebo in Prostate Cancer

  A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency
  

  ---

• A Phase 3 study of Cabozantinib + Atezolizumab in Subjects with Metastatic Castration-Resistant Pros

  A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
  

  ---

• Phase 3 Study of Niraparib in Prostate Cancer

  A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
  

  ---

• Phase 3 of Rucaparib vs. Physician Choice in Prostate Cancer

  A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
  

  ---

• Phase 1b Study of Cabozantinib +/- Atezolizumab in Locally Advanced or Metastatic Solid Tumors

  A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
  

  ---

• Enzalutamide +/- Pembrolizumab in Prostate Cancer

  A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  

  ---

Renal

• Phase 2 Study of MK-6482 in Renal Cell Patients

  Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
  

  ---

• Phase 3 Study of MK-6482 with Lenvatinib for Metastatic Renal Cell Cancer Patients

  An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen
  

  ---

Solid Tumors

• A Phase 1 study of SEA-TGT in subjects with Advanced Malignancies

  A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
  

  ---

• A Phase 1b/2 study of XMT-1536 in solid tumors

  A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)
  

  ---

• A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors

  A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
  

  ---

• A Phase 1/2 Study of BLU-667 in Advanced Solid Tumors

  A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC), and Other Advanced Solid Tumors
  

  ---

• A Phase 1b/2 study of Carvrotolimod + Pembrolizumab or Cemiplimab in Solid Tumors

  Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab
  

  ---

• A Phase 2 study of Sacituzumab Govitecan in Solid Tumors

  A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors
  

  ---

• Phase 2 Study of Erdafitinib in Solid Tumors

  A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
  

  ---